NPPA revised Ceiling price of 53 scheduled formulations: February 2023

Download NPPA notification No. S.O. S.O. 484(E) dt 02-02-2023, the link is given below:

2008
NPPA National Pharmaceutical Pricing Authority
Picture: Pixabay

Last Updated on December 31, 2023 by The Health Master

Download NPPA notification No. S.O. S.O. 484(E) dt 02-02-2023, the link is given below: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 53 scheduled formulations vide vide S.O. 484(E) dt 02-02-2023 based on the decision of 108th Authority meeting dated 27.01.2023

This price fixation followed the decision of the 108th Authority meeting on January 27, 2023.

In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO 1499(E) dated 30th March, 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods
and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table is given below the article

Note:
(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO 2013.

The manufacturer shall issue a price list in Form–V from the date of the Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of the production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.

Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

NPPA updated price lists: Download

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

National List of Essential Medicines (NLEM)

NPPA fixed retail price of 18 formulations: February 2023

NPPA fixed Ceiling price of 17 scheduled formulations: January 2023

NPPA revised Ceiling price of 111 scheduled formulations: January 2023

NPPA fixes retail price of 12 formulations: January 2023

NPPA revised Retail Price of 93 scheduled formulations: January 2023

NPPA fixes Retail Price of 4 scheduled formulations: January 2023

Pharma companies restrained from making Diabetes drug

India to spend $79.6 million to strengthen Drug Regulatory system

Drug recall: These Lots of Levothyroxine sodium Oral Solution recalled

NPPA fixed retail price of 18 formulations: February 2023

FDA Chhattisgarh raided various places and seized huge quantity of fake medicines

Latest IPC Alert – Indian Pharmacopoeia Commission

NSQ Drug: Route cause analysis and CAPA

DCGI allows relabeling & re-stickering of drugs: Rule 104A

Area required for manufacturing of Drugs, Cosmetics, Homoeopathic & Blood Centre

Latest Notifications regarding Pharmaceuticals

Table

  Sl. No.Name of the Scheduled Formulation  Dosage form and strength  Unit  Ceiling Price (Rs.)
(1)(2)(3)(4)(5)
1OmeprazoleCapsule 20 mg1 Capsule2.56
2ColchicineTablet 0.5mg1 Tablet2.91
3AmoxicillinCapsule 500mg1 Capsule6.56
4DexamethasoneTablet 0.5mg1 Tablet0.20
5PrednisoloneTablet 10mg1 Tablet1.07
6PrednisoloneTablet 5mg1 Tablet0.61
7AzithromycinTablet 250mg1 Tablet10.39
8AzithromycinTablet 500mg1 Tablet21.02
9PrednisoloneTablet 20mg1 Tablet2.14
10DoxycyclineCapsule 100mg1 Capsule2.75
11ParacetamolTablet 500mg1 Tablet0.80
12Sodium ValproateOral liquid 200mg/5mL(p)1 ML0.58
  13  CholecalciferolSolid oral dosage form 60000 IU Tablets  1 Tablet  20.07
14GefitinibTablet 250mg1 Tablet211.49
  15Mycophenolate mofetil  Tablet 250mg  1 Tablet  44.24
16CeftazidimePowder for Injection 250 mg1 Vial70.52
17XylometazolineNasal drops 0.05 %1 ML3.74
18XylometazolineNasal drops 0.1%1 ML4.57
  19  Bisacodyl  Suppository 5mg1 Suppository  8.90
20LevetiracetamInjection 100mg/mL1 ML20.53
21OndansetronInjection 2mg/mL1 ML5.32
  22  Paracetamol  Suppository 80mg1 Suppository  5.94
  23  Paracetamol  Suppository 170mg1 Suppository  7.09
24MethylergometrineInjection 0.2mg/mL1 ML13.33
  25Cytosine arabinoside  Injection 100mg/vial  1 Vial  124.49
  26Cytosine arabinoside  Injection 500mg/vial  1 Vial  478.32
27KetamineInjection 50mg/mL1 ML10.81
28VincristineInjection 1mg/mL1 ML51.30
  29  TramadolInjection 50mg/mL (upto 2ml pack)  1 ML  10.51
30OxytocinInjection 5 IU/mL1 ML15.91
31AzithromycinOral liquid 200 mg/5 mL (p)1 ML3.04
32CetirizineOral liquid 5mg/5mL(p)1 ML0.59
  33Amoxicillin (A) +Clavulanic acid (B)Oral liquid 200 mg (A) + 28.5mg(B)/5 mL(p)  1 ML  1.80
34CefiximeOral liquid 50 mg/5 mL (p)1 ML1.45
35CefiximeOral liquid 100mg/5mL(p)1 ML2.13
36RituximabInjection 10mg/mL1 ML679.41
37Sodium bicarbonateInjection (as per IP) – 8.4%1 ML1.20
38PrimaquineTablet 15mg1 Tablet4.58
39RitonavirTablet 100mg1 Tablet26.05
40CarbamazepineTablet 100mg1 Tablet0.95
41IbuprofenOral liquid 100mg/5mL(p)1 ML0.20
    42Zidovudine (A) +Lamivudine (B) +Nevirapine(C)Tablet 300mg(A)+150mg(B)+200mg (c)    1 Tablet    18.85
43SpironolactoneTablet 25mg1 Tablet1.95
44FurosemideTablet 40mg1 Tablet0.81
45VerapamilTablet 80 mg1 Tablet1.42
46VerapamilTablet 40mg1 Tablet0.77
47NatamycinDrops 5%1 ML20.85
48HomatropineDrops 2%1 ML5.71
  49Carboxymethyl cellulose  Drops 0.5%  1 ML  10.97
  50Carboxymethyl cellulose  Drops 1%  1 ML  14.79
  51  SalbutamolInhalation (MDI/DPI*) 100mcg/dose  1 MDI  0.44
  52  SalbutamolRespirator Solution (Solution for Nebulizer 5mg/mL)  1 ML  0.61
53PyridoxineTablet 100 mg1 Tablet5.33

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news